HOME >> MEDICINE >> NEWS
Problems at World Anti-Doping Agency will 'drive innocent athletes out of sport'

The current approach of the international agency responsible for fighting the use of drugs in sport will drive innocent athletes out of the Olympic Games, according to an article in the International Journal of Sports Science and Coaching.

The World Anti-Doping Agency (WADA) was set up in 1999 by the International Olympic Committee and publishes the list of banned substances and monitors drug use in sport through random tests.

In a review of some of the practices and procedures used by WADA, a leading sports scientist from the USA and a top marathon coach from the UK have identified major problems that they believe will lead to innocent athletes paying the price for a flawed anti-doping system.

Key to their finding was a lack of scientific evidence and protocol at the heart of WADA's operations.

"Drug testing and classification should be a scientific affair, unfortunately WADA appears to have little to no understanding of the criteria for science," said Dr Brent Rushall from San Diego State University, a four-time Olympic Team psychologist for Canada, who co-wrote the article with Max Jones, a multiple age-group world-record holding runner who has studied the drugs in sport movement.

"The actions and scope of WADA are causes for grave concern for the anti-drugs in sport movement. It is inevitable that if WADA continues its practices, professional athletes will be driven out of the Olympic Games."

Problems identified by the authors include:

  • Substances included in WADA's banned list are based on speculation rather than scientific evidence
  • WADA's clandestine sample collection procedures appear to ignore basic scientific guidelines
  • The way WADA lists banned substances does not conform to usual scientific practice, leading to confusion for coaches and athletes

    The authors cite the hysteria surrounding Anabolic Androgenic Steroids (AAS) as an example of WADA's poor use of science.
    '"/>



  • Contact: Dr Brent Rushall
    brushall@cox.net
    1-619-469-1537
    University of Bath
    17-Feb-2006


    Page: 1 2 3

    Related medicine news :

    1. Worlds largest respiratory health study launches next phase
    2. World first medical treatment announced by researchers
    3. World-leading innovation in child-allergy detection
    4. World-renowned chemist honored with inaugural lectureship
    5. IOF World Congress on Osteoporosis to be held for first time in Asia
    6. World first in medical robotics
    7. Worldwide Parkinsons cases will double in next 25 years
    8. Worldmapper draws attention to the worlds health inequalities
    9. World-class Biomedical Research Center to be in West London
    10. Worlds largest clinical trial into rare bone cancer well underway conference hears
    11. World-wide warning of highly drug-resistant tuberculosis

    Post Your Comments:
    (Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
    (Date:10/22/2014)... Lintelus, Inc., an event software provider, announced ... will be speaking on the subject of “Event Technology ... 28, at the Holiday Inn in New York City. ... as a Tech Demo at 12:45pm, to educate event ... engaging event experience. , The Annual Meetings Technology Expo ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
    (Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
    (Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
    Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
    (Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, Inc. ... results from the  IAP310 study have been published ... a peer-reviewed journal with broad, multidisciplinary readership. ... evaluating the safety and efficacy of Zalviso, also ... (SSTS), for the treatment of post-operative pain in ...
    (Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
    (Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( www.pneumrx.com ... today announced completion of enrollment in their RENEW Study, ... Study is the FDA-approved IDE pivotal trial for the ... It was anticipated that the study, which ... would take until the end of 2014 to enroll ...
    Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
    Cached News: